Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs OneSpan Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while OneSpan Inc trades at $17.52 (market cap $670.71M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is the larger of the two by market cap, and OneSpan Inc pays a 2.86% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and OneSpan Inc for 18 Days on average.
| MRVI | OSPN | |
|---|---|---|
Market Cap | $972.90M | $670.71M |
Volume | 4,325,710 | 364,626 |
Sector | Health | Technology |
52-Week High | $9.00 | $18.42 |
52-Week Low | $2.83 | $10.15 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $1.08B | $639.79M |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
OneSpan (OSPN) trades at $18.20, up 1.96% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with a 73.58% gross margin and consistent earnings beats, though net cash flow turned negative in 2026. Recent product innovation with DigipassONE and positive analyst coverage support the current valuation.
The outlook remains positive given strong profitability metrics and analyst consensus, but investors should monitor cash flow trends and competitive pressures in the cybersecurity sector. The stock's current valuation appears reasonable with a P/E of 10.28, offering potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
